Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia
Ward, M., Fang, G., Richards, K., Walko, C., Earnshaw, S., & Happe, L. (2015). Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. Journal of Health Economics, 2(2), 181-91.
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Meet the Experts
View All ExpertsRecent Publications
OCCASIONAL PAPER
Bringing an equity-centered framework to research
OCCASIONAL PAPER
The Preschool Entitlement
OCCASIONAL PAPER
Culturally informed community engagement
Article